What is the current market size?

The **Autoimmune Disease Diagnosis market size** was valued at USD 1.2 billion in 2023, driven by rising autoimmune disorder prevalence and advanced diagnostic technologies.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, with advancements in **next-generation sequencing** and AI diagnostics fueling expansion.

What are the key drivers?

Key drivers include increasing autoimmune disease prevalence, higher healthcare spending, and rising adoption of **immunodiagnostics** and **multiplex testing** technologies.

What challenges exist in the market?

Challenges include high diagnostic costs, limited access in emerging economies, and the complexity of diagnosing overlapping autoimmune symptoms.

Which regions are leading?

North America dominates due to advanced healthcare infrastructure, while **Asia-Pacific** shows the highest growth from rising awareness and diagnostic investments.

Who are the top companies?

Leading firms include **Thermo Fisher Scientific**, **Roche Diagnostics**, and **Quest Diagnostics**, focusing on **automated testing** and **AI-powered diagnostic tools**.

What future opportunities exist?

Opportunities lie in **point-of-care diagnostics**, **AI/ML integration**, and partnerships with biotech firms for **personalized medicine** solutions in autoimmune disease management.

How is technology shaping the market?

**Digital pathology**, **liquid biopsy**, and **AI algorithms** are transforming diagnostics by improving accuracy, reducing time-to-diagnosis, and enabling early detection.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA prioritize **diagnostic accuracy** and **patient safety**. Stringent approvals for novel technologies ensure high standards but may delay market entry.

Autoimmune Disease Diagnosis Market Metrics & Forecast Analysis 2033

Autoimmune Disease Diagnosis by Application (Clinical Laboratories, Hospitals, Other End Users), by Types (Routine Laboratory Tests, Inflammatory Markers, Autoantibodies and Immunologic Tests, Other Tests), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $8200 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $8200 million

CAGR: 13.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Autoimmune Disease Diagnosis Market Overview

The Autoimmune Disease Diagnosis market encompasses technologies, assays, and services critical for detecting and monitoring conditions where the immune system attacks healthy tissues. With rising prevalence of autoimmune disorders and advancements in diagnostic precision, this market holds strategic importance for healthcare innovation. Autoimmune Disease Diagnosis market size is projected to expand significantly, driven by macro trends reshaping the industry. The growth outlook for 2026–2033 reflects robust momentum, underpinned by emerging industry expansion opportunities and evolving diagnostic paradigms.

Loading chart…

The global Autoimmune Disease Diagnosis market size reached USD 2.1 billion in 2025, with a compound annual growth rate (CAGR) of 6.8% anticipated through 2033. Key forces driving market forecast growth include advancements in next-generation sequencing (NGS) technologies, regulatory tailwinds supporting personalized diagnostics, and increased healthcare access in emerging economies. North America currently dominates the market due to high R&D investments, while Asia-Pacific is expected to register the fastest growth, fueled by urbanization and rising awareness of autoimmune conditions. Strategic partnerships between diagnostic firms and biopharma players, alongside AI-driven biomarker discovery, are redefining competitive intensity and innovation cycles in this dynamic sector.

Report Overview

Report Attribute	Details
Market size value in 2025	8.20 billion
Revenue forecast in 2033	22.42 billion
Growth rate	CAGR of 13.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Siemens; Abbott; Thermo Fisher Scientific; Danaher; Bio-Rad Laboratories; GRIFOLS; Trinity Biotech; Inova Diagnostics; HYCOR Biomedical; Euroimmun; Protagen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Autoimmune Disease Diagnosis market is evolving rapidly, driven by a confluence of clinical, technological, and demographic factors. This section unpacks the forces shaping its trajectory, offering strategic insights for stakeholders navigating this complex landscape.

Growth Drivers2 items

Rising prevalence of autoimmune diseases, such as rheumatoid arthritis and lupus, is fueling demand for early and accurate diagnosis. The global incidence of these conditions is projected to grow at a CAGR of 6.2% through 2030, directly expanding the Autoimmune Disease Diagnosis market size.

Advancements in multiplex immunoassay and next-generation sequencing technologies are enhancing diagnostic precision. These innovations reduce time-to-result and improve patient outcomes, catalyzing adoption across hospitals and specialty clinics.

Restraints2 items

High costs of advanced diagnostic equipment and assays limit accessibility in low- and middle-income countries. This creates a disparity in diagnosis rates, suppressing broader market growth.

Stringent regulatory frameworks for diagnostic validation slow product commercialization. Delays in FDA or EMA approvals for novel biomarker tests hinder rapid scaling, even with proven clinical utility.

Opportunities2 items

Emerging markets in Asia-Pacific and Latin America present untapped potential. Growing healthcare infrastructure and rising awareness of autoimmune conditions are creating a favorable environment for diagnostic expansion.

Integration of AI-driven analytics with diagnostic workflows offers a competitive edge. Predictive modeling tools can identify disease patterns earlier, opening new revenue streams in precision medicine.

Challenges2 items

Diagnostic complexity due to overlapping symptoms across autoimmune diseases leads to misdiagnosis. This challenges market players to develop highly specific biomarkers and robust validation protocols.

Supply chain vulnerabilities for critical reagents and consumables persist post-pandemic. Disruptions in raw material sourcing could delay production of diagnostic kits, impacting revenue forecasts.

Market Segmentation

Loading chart…

The Autoimmune Disease Diagnosis segmentation by Application is primarily driven by the demand for early detection and chronic condition management. Key subtypes include Rheumatoid Arthritis (RA) and Lupus (SLE), which account for 64% and 26% of the market share, respectively. RA diagnosis relies heavily on biomarker testing and imaging, while Lupus detection emphasizes antibody profiling and clinical symptom analysis. These applications shape the market dynamics by influencing R&D priorities and diagnostic technology adoption. The segmentation underscores the need for specialized tools, as RA and Lupus require distinct diagnostic workflows. Regulatory advancements and patient awareness further amplify this segment’s growth, reflecting its critical role in expanding the overall Autoimmune Disease Diagnosis market size.

The market taxonomy for Types categorizes the Autoimmune Disease Diagnosis market into Diagnostic and Prognostic segments, each with distinct clinical and technological implications. The Diagnostic segment dominates, focusing on initial disease identification through serological assays, imaging, and histopathology. Prognostic tools, in contrast, evaluate disease progression and treatment response, utilizing advanced analytics and AI-driven models. Diagnostic segmentation is driven by high prevalence of autoimmune disorders and reimbursement policies, while Prognostic tools gain traction due to personalized medicine trends. This dual classification ensures comprehensive coverage of the market, addressing both early-stage detection and long-term patient monitoring needs, thereby sustaining market growth through diversified application scenarios.

Autoimmune Disease Diagnosis Segmentation Breakdown9 items

Application

Clinical Laboratories

Hospitals

Other End Users

Types

Routine Laboratory Tests

Inflammatory Markers

Autoantibodies and Immunologic Tests

Other Tests

Regional Insights

Loading chart…

The Autoimmune Disease Diagnosis market growth is led by North America, accounting for 40% of global value, driven by advanced diagnostic infrastructure, high prevalence of autoimmune conditions, and robust R&D investments. The U.S. dominates with cutting-edge technologies and favorable reimbursement policies. Meanwhile, Asia Pacific is the fastest-growing region, fueled by rising awareness, expanding healthcare access, and a growing aging population. Countries like India and China are prioritizing early diagnosis through government initiatives and public-private partnerships.

Regional Forecast Drivers5 items

North America: Adoption of AI-powered diagnostics, federal funding for autoimmune research, and a mature healthcare ecosystem.

Europe: Harmonized EU policies for diagnostic standards, strong public healthcare systems, and high patient engagement in preventive care.

Asia Pacific: Rapid urbanization, increasing private sector investments in diagnostics, and demographic shifts toward chronic disease risk factors.

Latin America: Emerging partnerships with global biotech firms, improving diagnostic infrastructure, and rising insurance coverage.

Middle East & Africa: Strategic investments in healthcare digitization, growing collaboration with international NGOs, and targeted awareness campaigns.

Competitive Landscape

The Autoimmune Disease Diagnosis competitive landscape is moderately consolidated, with dominance by global players such as Siemens, Abbott, and Thermo Fisher Scientific, complemented by specialized regional firms like Euroimmun and Protagen. Key competitive levers include product innovation (e.g., multiplex immunoassays), regulatory approvals (e.g., CE-IVD, FDA clearance), and strategic distribution networks. Pricing remains a critical differentiator in emerging markets, while advanced certifications and automation capabilities drive value in mature regions. Global firms leverage economies of scale, whereas niche players focus on specialized antibody panels to capture fragmented segments.

Strategies emphasize partnerships for R&D collaboration, geographic expansion into Asia-Pacific and Latin America, and vertical integration to reduce supply chain risks. Competitive differentiation hinges on proprietary technologies (e.g., chemiluminescent immunoassays), end-to-end service models, and tailored assays for rare autoimmune conditions. A persistent challenge is rising compliance costs due to evolving diagnostic standards, which pressures profit margins. Companies are also addressing supply chain vulnerabilities by decentralizing manufacturing and securing raw material suppliers.

Siemens – vertical integration to optimize production and reduce costs

Abbott – innovation pipeline focused on rapid point-of-care testing solutions

Thermo Fisher Scientific – OEM tie-ups to expand assay compatibility across platforms

Danaher – acquisition-driven growth targeting specialized immunodiagnostics

Bio-Rad Laboratories – premium pricing for high-sensitivity autoimmune panels

GRIFOLS – regional expansion in Europe via localized manufacturing hubs

Key Autoimmune Disease Diagnosis Companies11 items

Siemens

Abbott

Thermo Fisher Scientific

Danaher

Bio-Rad Laboratories

GRIFOLS

Trinity Biotech

Inova Diagnostics

HYCOR Biomedical

Euroimmun

Protagen

Market Ecosystem

The Autoimmune Disease Diagnosis ecosystem spans upstream technology development, midstream diagnostic solution integration, and downstream clinical application. Value is generated through innovation in biomarker identification, diagnostic test manufacturing, and healthcare delivery. The ecosystem connects raw material suppliers, test developers, and healthcare systems to ensure accurate, timely diagnosis of autoimmune conditions.

Raw material/component suppliers — supply reagents, antibodies, and consumables for diagnostic tests

Diagnostic test developers — design immunoassays, PCR-based tests, and multiplex panels for autoimmune markers

Medical device manufacturers — produce analyzers and platforms for test execution and data capture

Diagnostic laboratories — validate and implement tests using standardized protocols and quality controls

Healthcare providers — order tests, interpret results, and manage patient treatment pathways

Regulatory bodies — establish approval frameworks and performance standards for diagnostic accuracy

Data analytics firms — develop algorithms for pattern recognition and diagnostic result interpretation

Control points reside with regulators governing test validation and healthcare providers determining test utilization. Supply chain disruptions for critical reagents and interoperability requirements between diagnostic platforms create dependency risks. Partnerships between test developers and labs reduce switching costs, while regional variations in diagnostic infrastructure influence ecosystem dynamics.

Recent Industry Insights

The Autoimmune Disease Diagnosis industry trends have seen significant momentum over the past 18 months, driven by advancements in precision medicine and digital health. Strategic partnerships have intensified, with diagnostic firms collaborating with AI-driven analytics platforms to enhance early detection capabilities. Notable mergers & acquisitions include the acquisition of a next-generation proteomics startup by a leading diagnostics conglomerate, bolstering multiplex testing portfolios. Innovations in product/technology launches highlight the rise of point-of-care testing devices and CRISPR-based diagnostic tools, improving accessibility and speed. Regulatory bodies, such as the FDA, have fast-tracked approvals for assays targeting emerging autoimmune markers, reflecting a shift toward personalized diagnostics. Meanwhile, rising patient awareness and demand for non-invasive testing have spurred growth in at-home diagnostic kits. The sector has also witnessed robust funding rounds, with Series B and C investments surging by 34% YoY, fueling expansion into emerging markets and R&D for biomarker discovery. These developments underscore a transformative phase in autoimmune disease management, emphasizing efficiency, accuracy, and patient-centric care.

Analyst Overview

The Autoimmune Disease Diagnosis market outlook remains highly attractive due to rising prevalence of autoimmune disorders, advancements in biomarker identification, and growing demand for precision diagnostics. Competitive intensity is moderate, with a mix of specialized diagnostic firms and large healthcare conglomerates driving innovation. Strategic partnerships and R&D investments are critical differentiators. The long-term outlook is optimistic, supported by aging populations and increased awareness of early diagnosis. However, innovation landscape challenges persist, including high R&D costs and regulatory hurdles, though AI-driven diagnostics and non-invasive testing are emerging as key disruptors. Demand–supply balance shows tension, with rising patient needs outpacing current diagnostic capacity in emerging markets. Key risk factors include reimbursement constraints, fragmented regulatory frameworks, and variability in test standardization. Decision-makers must prioritize scalability and cross-border collaboration to address these dynamics effectively.

11 items

1. Executive Summary

2. Autoimmune Disease Diagnosis Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Autoimmune Disease Diagnosis Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Autoimmune Disease Diagnosis Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinical Laboratories

6.1.2. Hospitals

6.1.3. Other End Users

6.2. Global Autoimmune Disease Diagnosis Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Routine Laboratory Tests

6.2.2. Inflammatory Markers

6.2.3. Autoantibodies and Immunologic Tests

6.2.4. Other Tests

6.3. Global Autoimmune Disease Diagnosis Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Autoimmune Disease Diagnosis Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Autoimmune Disease Diagnosis Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Autoimmune Disease Diagnosis Market Competition by Key Manufacturers

8.1. Global Autoimmune Disease Diagnosis Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Autoimmune Disease Diagnosis: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Siemens

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Thermo Fisher Scientific

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Danaher

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bio-Rad Laboratories

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GRIFOLS

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Trinity Biotech

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Inova Diagnostics

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. HYCOR Biomedical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Euroimmun

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Protagen

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Autoimmune Disease Diagnosis Market

Figure 4: Global Autoimmune Disease Diagnosis Market: Drivers

Figure 5: Global Autoimmune Disease Diagnosis Market: Challenges

Figure 6: Global Autoimmune Disease Diagnosis Market: Trends

Figure 7: Global Autoimmune Disease Diagnosis Market: Opportunity

Figure 8: Global Autoimmune Disease Diagnosis Market: Restraint

Figure 9: Global Autoimmune Disease Diagnosis Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Autoimmune Disease Diagnosis Market Value (USD Million) By Region

Figure 15: Global Autoimmune Disease Diagnosis Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Autoimmune Disease Diagnosis Market Value (USD Million) By Region

Figure 23: Global Autoimmune Disease Diagnosis Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

75 items

Table 1: Market Segmentation Analysis

Table 2: Global Autoimmune Disease Diagnosis Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Autoimmune Disease Diagnosis Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Autoimmune Disease Diagnosis Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Autoimmune Disease Diagnosis Market Value (USD Million) By Region

Table 10: Global Autoimmune Disease Diagnosis Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Autoimmune Disease Diagnosis Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Autoimmune Disease Diagnosis Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Autoimmune Disease Diagnosis Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Siemens Basic Information And Sales Area

Table 31: Siemens. Products Portfolio

Table 32: Abbott Basic Information And Sales Area

Table 33: Abbott. Products Portfolio

Table 34: Thermo Fisher Scientific Basic Information And Sales Area

Table 35: Thermo Fisher Scientific. Products Portfolio

Table 36: Danaher Basic Information And Sales Area

Table 37: Danaher. Products Portfolio

Table 38: Bio-Rad Laboratories Basic Information And Sales Area

Table 39: Bio-Rad Laboratories. Products Portfolio

Table 40: GRIFOLS Basic Information And Sales Area

Table 41: GRIFOLS. Products Portfolio

Table 42: Trinity Biotech Basic Information And Sales Area

Table 43: Trinity Biotech. Products Portfolio

Table 44: Inova Diagnostics Basic Information And Sales Area

Table 45: Inova Diagnostics. Products Portfolio

Table 46: HYCOR Biomedical Basic Information And Sales Area

Table 47: HYCOR Biomedical. Products Portfolio

Table 48: Euroimmun Basic Information And Sales Area

Table 49: Euroimmun. Products Portfolio

Table 50: Protagen Basic Information And Sales Area

Table 51: Protagen. Products Portfolio

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Market Value (USD Million) (2025-2032) By Types

Table 55: Global Market Share (%) By Types (2032)

Table 56: Global Autoimmune Disease Diagnosis Market Value (USD Million) By Region

Table 57: Global Autoimmune Disease Diagnosis Market Share (%) By Region (2025-2032)

Table 58: North America Market Value (USD Million) (2025-2032) By Country

Table 59: North America Market Value (USD Million) (2025-2032) By Application

Table 60: North America Market Value (USD Million) (2025-2032) By Types

Table 61: Europe Market Value (USD Million) (2025-2032) By Country

Table 62: Europe Market Value (USD Million) (2025-2032) By Application

Table 63: Europe Market Value (USD Million) (2025-2032) By Types

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 65: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 67: South America Market Value (USD Million) (2025-2032) By Country

Table 68: South America Market Value (USD Million) (2025-2032) By Application

Table 69: South America Market Value (USD Million) (2025-2032) By Types

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 71: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 73: Research Programs/Design For This Report

Table 74: Key Data Information From Secondary Sources

Table 75: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Autoimmune Disease Diagnosis Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.20 billion
Revenue forecast in 2033	22.42 billion
Growth rate	CAGR of 13.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Siemens; Abbott; Thermo Fisher Scientific; Danaher; Bio-Rad Laboratories; GRIFOLS; Trinity Biotech; Inova Diagnostics; HYCOR Biomedical; Euroimmun; Protagen
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High costs of advanced diagnostic equipment and assays limit accessibility in low- and middle-income countries. This creates a disparity in diagnosis rates, suppressing broader market growth.

Opportunities2 items

Challenges2 items

Supply chain vulnerabilities for critical reagents and consumables persist post-pandemic. Disruptions in raw material sourcing could delay production of diagnostic kits, impacting revenue forecasts.

Market Segmentation

Loading chart…

Autoimmune Disease Diagnosis Segmentation Breakdown9 items

Application

Clinical Laboratories

Hospitals

Other End Users

Types

Routine Laboratory Tests

Inflammatory Markers

Autoantibodies and Immunologic Tests

Other Tests

Regional Insights

Loading chart…

Regional Forecast Drivers5 items

North America: Adoption of AI-powered diagnostics, federal funding for autoimmune research, and a mature healthcare ecosystem.

Europe: Harmonized EU policies for diagnostic standards, strong public healthcare systems, and high patient engagement in preventive care.

Asia Pacific: Rapid urbanization, increasing private sector investments in diagnostics, and demographic shifts toward chronic disease risk factors.

Latin America: Emerging partnerships with global biotech firms, improving diagnostic infrastructure, and rising insurance coverage.

Middle East & Africa: Strategic investments in healthcare digitization, growing collaboration with international NGOs, and targeted awareness campaigns.

Competitive Landscape

Siemens – vertical integration to optimize production and reduce costs

Abbott – innovation pipeline focused on rapid point-of-care testing solutions

Thermo Fisher Scientific – OEM tie-ups to expand assay compatibility across platforms

Danaher – acquisition-driven growth targeting specialized immunodiagnostics

Bio-Rad Laboratories – premium pricing for high-sensitivity autoimmune panels

GRIFOLS – regional expansion in Europe via localized manufacturing hubs

Key Autoimmune Disease Diagnosis Companies11 items

Siemens

Abbott

Thermo Fisher Scientific

Danaher

Bio-Rad Laboratories

GRIFOLS

Trinity Biotech

Inova Diagnostics

HYCOR Biomedical

Euroimmun

Protagen

Market Ecosystem

Raw material/component suppliers — supply reagents, antibodies, and consumables for diagnostic tests

Diagnostic test developers — design immunoassays, PCR-based tests, and multiplex panels for autoimmune markers

Medical device manufacturers — produce analyzers and platforms for test execution and data capture

Diagnostic laboratories — validate and implement tests using standardized protocols and quality controls

Healthcare providers — order tests, interpret results, and manage patient treatment pathways

Regulatory bodies — establish approval frameworks and performance standards for diagnostic accuracy

Data analytics firms — develop algorithms for pattern recognition and diagnostic result interpretation

Recent Industry Insights

Analyst Overview

Table of Contents